RecruitingNCT06574399

Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Enrollment

1,000 participants

Start Date

May 1, 2023

Study Type

OBSERVATIONAL

Conditions

Staphylococcus Aureus Bacteremia

Summary

The goal of this observational study is to determine retrospectively whether different patient clinical phenotypes (adults and children) develop Staphylococcus aureus bacteremia.The main questions it aims to answer qre: 1. Evaluate its reproducibility and correlation with mortality 2. Derive and validate a simplified probabilistic model for phenotype assignment 3. External validation of the simplified probabilistic phenotype assignment model found and its association with mortality and development of complicated bacteremia in a prospective cohort 4. Apply microbiological, biochemical and immunological techniques to explain the physiopathological and genetic mechanisms underlying the phenotypes.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

FOR STANDARD STUDY:
Adults and children with clinically significant Staphylococcus aureus bacteremia (at least two classic systemic inflammatory response criteria: fever, tachycardia, tachypnea, lowered awareness, low blood pressure, leucocytosis/leucopenia, organ failure)
Adults with clinically significant Staphylococcus aureus bacteremia included in the Standard Study
Selected at random as one of the model phenotypes until completing recruitment (only HUVM and HUVV)

Exclusion Criteria9

Patients with non-clinically significant bacteremia.
Death within 48 hours after detection of bacteremia for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases.
Patients under palliative sedation at the time of bacteremia report.
Polymicrobial bacteremia.
FOR EXTENDED STUDY:
Patients with non-clinically significant bacteremia.
Death within 48 hours after detection of bacteremia for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases.
Patients under palliative sedation at the time of bacteremia report.
Polymicrobial bacteremia.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.